Changing Lifestyle and Increase in Lifestyle Disorders Favor the Growth of Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Market is predicted to reach USD 6.65 billion at a CAGR of 6.80% during the forecast period:

Market Research Future (MRFR) has published a cooked research report on the “Global Erectile Dysfunction Drugs Market” that contains information from 2018 to 2030. The Erectile Dysfunction Drugs market is estimated to register a CAGR of 6.80% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the global Erectile Dysfunction Drugs market— Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.

Erectile Dysfunction Drugs Market Highlights

The global Erectile Dysfunction Drugs market is accounted to register a CAGR of 6.80% during the forecast period and is estimated to reach USD 6.65 billion by 2030.

The erectile dysfunction drugs market pertains to the pharmaceutical industry focused on developing and marketing medications for the treatment of erectile dysfunction. These drugs, such as Viagra, Cialis, and Levitra, help enhance blood flow to the penis, enabling men with erectile dysfunction to achieve and maintain erections, thereby improving their sexual function and quality of life.

Segment Analysis

The global Erectile Dysfunction Drugs market has been segmented based on Product Type and end-user.

On the basis of Product Type, the market is segmented into viagra, cialis, stendra/spedra, Zydena, Vitaros, and others. The market for erectile dysfunction medications was dominated by the viagra category in 2022, accounting for over 35% of total market revenue. Research collaborations, agreements, and partnerships are just a few of the strategic actions that many companies are currently doing to increase their market dominance.

Based on End User, the global Erectile Dysfunction Drugs market has been segmented into Hospital pharmacies, Retail Pharmacies, Online Pharmacies, and others. Due to the drug's accessibility and the market's rising ED cases, retail pharmacies maintained the largest segment share in 2022. Retail pharmacies are a blessing in disguise for many patients who are hesitant to enter a store to purchase erectile dysfunction drugs and other sexual wellness products.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Erectile Dysfunction Drugs Market Research Report

Regional Analysis

The global Erectile Dysfunction Drugs market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Erectile Dysfunction Drugs market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Erectile Dysfunction Drugs market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Erectile Dysfunction Drugs market comprises of Middle East, Africa, and Latin America.

The North America Erectile Dysfunction Drugs Market dominated this market in 2022 USD 1.92 billion in 2022 and is anticipated to increase at a notable CAGR during the research period. The high prevalence of illness, the effective healthcare system, and the acceptance of cutting-edge medicinal products are the causes of this.

Additionally, the second-largest market share for Erectile Dysfunction Drugs is held by Europe. The expanding geriatric population in this region, along with numerous product launches by significant market rivals, are expected to fuel market progress. Additionally, the UK's market for erectile dysfunction medications grew at the highest rate in the European region, while Germany's market for erectile dysfunction medications held the largest market share.

The market for erectile dysfunction medications in Asia-Pacific is anticipated to expand at the quickest CAGR between 2022 and 2030. The region has grown as a result of the introduction of new products. For instance, in May 2020, iX Biopharma announced that it would provide Wafesil and Silcap via telemedicine to Australia in order to treat an adult patient with erectile dysfunction. Additionally, the Asia-Pacific region's Erectile Dysfunction Drugs market in India grew at the fastest rate, while the market in China held the greatest market share.

Key Findings of the Study

• The global Erectile Dysfunction Drugs market is expected to reach USD 6.65 billion by 2030, at a CAGR of 6.80% during the forecast period.


• The North America Erectile Dysfunction Drugs Market dominated this market in 2022 USD 1.92 billion in 2022 and is anticipated to increase at a notable CAGR during the research period.


• Based on Product Type, The market for erectile dysfunction medications was dominated by the viagra category in 2022, accounting for over 35% of total market revenue.


• Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.